Literature DB >> 16030190

Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders.

Clara Camaschella1.   

Abstract

Genetic analysis of hemochromatosis has led to the discovery of a number of genes whose mutations disrupt iron homeostasis and lead to iron overload. The introduction of molecular tests into clinical practice has provided a tool for early diagnosis of these conditions. It has become clear that hemochromatosis includes a spectrum of disorders that range from simple biochemical abnormalities to chronic asymptomatic tissue damage in midlife to serious life-threatening diseases in young subjects. Molecular studies have identified the systemic loop that controls iron homeostasis and is centered on the hepcidin-ferroportin interaction. The complexity of this regulatory pathway accounts for the genetic heterogeneity of hemochromatosis and related disorders and raises the possibility that genes encoding components of the pathway may be modifiers of the main genotype. Molecular diagnosis has improved the classification of the genetic conditions leading to iron overload and identified novel entities, characterized by both iron loading and variable degrees of anemia. Despite the progress in the diagnosis, classification, and mechanisms of iron overload disorders, the treatment of affected patients continues to rely on regular phlebotomy. Understanding the molecular circuitry of iron control may lead to the identification of potential therapeutic targets for novel treatment strategies to be used in association with or as an alternative to phlebotomy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030190     DOI: 10.1182/blood-2005-05-1857

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

1.  Assessment of iron absorption in mice by ICP-MS measurements of (57)Fe levels.

Authors:  Veronica Fiorito; Simonetta Geninatti Crich; Lorenzo Silengo; Fiorella Altruda; Silvio Aime; Emanuela Tolosano
Journal:  Eur J Nutr       Date:  2011-10-19       Impact factor: 5.614

Review 2.  Molecular control of vertebrate iron homeostasis by iron regulatory proteins.

Authors:  Michelle L Wallander; Elizabeth A Leibold; Richard S Eisenstein
Journal:  Biochim Biophys Acta       Date:  2006-05-17

3.  Molecular evolution of hemojuvelin and the repulsive guidance molecule family.

Authors:  Laura Marie Camus; Lisa A Lambert
Journal:  J Mol Evol       Date:  2007-06-25       Impact factor: 2.395

4.  Towards explaining "unexplained hyperferritinemia".

Authors:  Clara Camaschella; Erika Poggiali
Journal:  Haematologica       Date:  2009-03       Impact factor: 9.941

Review 5.  Forging a field: the golden age of iron biology.

Authors:  Nancy C Andrews
Journal:  Blood       Date:  2008-07-15       Impact factor: 22.113

6.  BMP6 orchestrates iron metabolism.

Authors:  Clara Camaschella
Journal:  Nat Genet       Date:  2009-04       Impact factor: 38.330

7.  The immunophilin FKBP12 inhibits hepcidin expression by binding the BMP type I receptor ALK2 in hepatocytes.

Authors:  Silvia Colucci; Alessia Pagani; Mariateresa Pettinato; Irene Artuso; Antonella Nai; Clara Camaschella; Laura Silvestri
Journal:  Blood       Date:  2017-09-01       Impact factor: 22.113

8.  Hereditary hemochromatosis: insights from the Hemochromatosis and Iron Overload Screening (HEIRS) Study.

Authors:  Gordon D McLaren; Victor R Gordeuk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2009

9.  The molecular mechanism of hepcidin-mediated ferroportin down-regulation.

Authors:  Ivana De Domenico; Diane McVey Ward; Charles Langelier; Michael B Vaughn; Elizabeta Nemeth; Wesley I Sundquist; Tomas Ganz; Giovanni Musci; Jerry Kaplan
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

10.  Association between iron overload and osteoporosis in patients with hereditary hemochromatosis.

Authors:  L Valenti; M Varenna; A L Fracanzani; V Rossi; S Fargion; L Sinigaglia
Journal:  Osteoporos Int       Date:  2008-07-26       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.